September 16, 1997, is amended as follows:

Paragraph 6005 Class E airspace areas extending upward from 700 feet or more above the surface of the earth.

* * * * *

AGL OH E5 Washington Court House, OH [Revised]

Washington Court House, Fayette County Airport, OH
(Lat. 39°34′ 13″N., long. 83°25′ 14″W.)
Court House NDB
(Lat. 39°35′ 58″N., long. 83°23′ 32″W.)

That airspace extending upward from 700 feet above the surface within a 6.5-mile radius of Fayette County Airport and within 6.4 miles either side of the 037° bearing from the Court House NDB, extending from the 6.5-mile radius to 7.0 miles northeast of the NDB, and within 2.2 miles either side of the 037° bearing from the Court House NDB, extending from the 6.5-mile radius to 10.0 miles northeast of the NDB.

* * * * *

Issued in Des Plaines, Illinois on January 22, 1998.

Maureen Woods,

Manager, Air Traffic Division.

[FR Doc. 98–3731 Filed 2–12–98; 8:45 am]

BILLING CODE 4910–13–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 201, 330, and 358

[Docket No. 96N–0420]

Over-the-Counter Human Drugs; Proposed Labeling Requirements; Notice of Availability of Study Data and Reopening of Comment Period

AGENCY: Food and Drug Administration, HHS.

ACTION: Proposed rule; reopening of comment period on specific data.

SUMMARY: The Food and Drug Administration (FDA) is reopening to March 30, 1998 the comment period on specific data related to the February 27, 1997, proposed rule to establish a standardized format for the labeling of over-the-counter (OTC) drug products (62 FR 9024). As part of that rulemaking proceeding, the agency collected data under a study entitled ''Evaluation of Proposed Over-the-Counter (OTC) Label Format Comprehension,'' (Study A). This document announces the availability of the data and frequency tabulations that summarize the Study A data and reopens the comment period for the OTC rulemaking proceeding to allow an opportunity for comment on Study A.

DATES: Submit written comments on Study A by March 30, 1998.

ADDRESSES: Submit written comments on the information collected in Study A to the Dockets Management Branch (HFA–305), ATTN: Study A, OTC Drug Labeling Data Collection, Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Kathryn J. Aikin, Food and Drug Administration, Division of Drug Marketing, Advertising, and Communications (HFD–40), 5600 Fishers Lane, Rockville, MD 20857, 301–827–2828, Aikink@cder.fda.gov.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of February 27, 1997 (62 FR 9024), FDA published a proposed rule intended to enable consumers to better read and understand OTC drug product labeling and to more effectively apply the information in the labeling to the safe and effective use of such products. An important element of FDA'S proposed rule is a standardized labeling format for OTC drug products.

After issuing the proposed rule, FDA published in the **Federal Register** a notice under the Paperwork Reduction Act of 1995 announcing the agency's intention to conduct four studies relating to OTC drug products (62 FR 28482, May 23, 1997). The agency intends at this time to use two of the studies (''Evaluation of Proposed Over-the-Counter (OTC) Label Format Comprehension, Study A,'' and ''Over-the-Counter (OTC) Label Format Preference, Study B'') in deliberations on developing a standardized, easy to read and easy to understand, labeling format for OTC drug products (see 62 FR 9024). In the **Federal Register** of December 30, 1997 (62 FR 67770), the agency requested comments specifically related to Study B. The data and frequency tabulations for Study A are now available.

In Study A, consumers were invited to view examples of OTC label designs. Respondents were asked questions designed to measure knowledge and attitudes about OTC drug products, as well as decisions about proper use of the products. The agency is now seeking comments on the data developed under Study A, including the participants' responses on the comprehension elements measured for the specific label designs viewed. The comments on Study A will be included in the agency's deliberations on developing a final, standardized OTC labeling format regulation.

Interested persons may, on or before March 30, 1998, submit written comments on the data developed under Study A to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document and labeled ''ATTN: Study A, OTC Drug Labeling Data Collection.'' The data, frequency tabulations, and received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. An electronic format of the data are available on the internet at: www.fda.gov/CDER/ or can be obtained in electronic form from the Dockets Management Branch at the address listed previously.

Dated: February 4, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–3625 Filed 2-12-98; 8:45 am]

BILLING CODE 4160–01–F

NATIONAL MEDIATION BOARD

29 CFR Part 1208

Freedom of Information Act, Implementation; Fee Schedule

AGENCY: National Mediation Board.

ACTION: Proposed rule.

SUMMARY: The National Mediation Board is proposing to amend its rule implementing the Freedom of Information Act (FOIA), as provided by the Freedom of Information Reform Act of 1986 (Pub. L. 99–570), which requires that the NMB promulgate regulations, pursuant to notice and receipt of public comment, specifying the schedule of fees applicable to the processing of FOIA requests and establishing procedures and guidelines for determining when such fees should be waived or reduced. The proposed revisions substantially conform to the Uniform Freedom of Information Act Fee Schedule and Guidelines published by the Office of Management and Budget in 52 FR 10012 (March 27, 1987).

DATES: Comments must be received by: March 16, 1998.

ADDRESSES: Send or deliver written comments to: Ronald M. Etters, General Counsel, 1301 K Street, N.W., Suite 250, Washington, D.C. 20572, Telephone (202) 523–5920.

SUPPLEMENTARY INFORMATION: The Freedom of Information Reform Act of 1986 (Pub. L. 99–570) requires agencies to adopt regulations that conform to the